Shares of AtriCure, Inc. (Nasdaq: ATRC) rose 6.4% to $34.12 in Wednesday morning buying and selling after the medical gadget maker reported fourth-quarter earnings that swung to a revenue and exceeded analyst expectations for income.
The inventory has traded in a 52-week vary of $21.45 to $38.90. Right now’s advance continues a restoration pattern from mid-2025 lows, although the shares stay roughly 12% beneath their yearly peak because the medical know-how sector faces broader strain from risky hospital capital gear budgets.
AtriCure reported fourth-quarter worldwide income of $140.5 million, a 13.1% improve in comparison with $124.2 million in the identical interval final 12 months. U.S. income climbed 12.6% to $114.3 million, pushed by demand for the cryoSPHERE MAX probe and AtriClip FLEX-Mini appendage administration gadget. Worldwide income grew 15.3% to $26.2 million.
The corporate posted fourth-quarter internet revenue of $1.8 million, or $0.04 per diluted share, in comparison with a internet lack of $15.6 million, or $0.33 per share, within the prior-year quarter. Adjusted EBITDA rose to $19.9 million from $12.7 million a 12 months in the past. Gross margin for the quarter was 75.0%, up 45 foundation factors year-over-year, supported by a extra favorable product combine.
For the complete 12 months 2025, complete income reached $534.5 million, representing 14.9% development over 2024. The annual internet loss narrowed considerably to $11.4 million, in comparison with a lack of $44.7 million within the earlier 12 months.
Whereas AtriCure operates within the med-tech house, its valuation stays delicate to macro pressures affecting high-growth “SaaS-adjacent” know-how shares. Excessive rates of interest have continued to weigh on growth-oriented equities, resulting in tighter valuation multiples throughout the software program and medical know-how sectors. Regardless of these pressures, AtriCure administration issued 2026 steerage projecting full-year income of $600 million to $610 million, representing roughly 12% to 14% development.
Administration attributed the improved profitability to operational leverage and price efficiencies. The corporate ended 2025 with a stronger steadiness sheet, positioning it to fund ongoing medical trials, together with the LeAAPs and BoxX-NoAF research.
Nonetheless, the corporate stays topic to regulatory and aggressive dangers. Any shifts in FDA clearance timelines for brand new product iterations or elevated competitors from catheter-based applied sciences might influence its 2026 development targets. Administration expects continued optimistic money era via 2026.
